

## Special Issue

# Hepatitis B Virus and Liver Cancer: Molecular Mechanisms and Approaches for the Prevention

### Message from the Guest Editor

Hepatitis B virus (HBV) infection is one of worldwide health problems because patients who were chronically infected with HBV are at risk of liver cirrhosis and liver cancer including hepatocellular carcinoma (HCC). Such patients are treated with nucleoside/nucleotide analogues or interferon, but the risk of liver cancer still remains during/after therapies. There seem to be several mechanisms of hepatocarcinogenesis due to HBV chronic infection, but it is not fully understood. In this special issue, we would like to accept manuscripts regarding the mechanisms for the development of HBV-associated liver cancer and its potential applications for therapies. Also, we would like to discuss the advantages and disadvantages of current and future therapies for the prevention of liver cancer.

### Guest Editor

Dr. Jun Inoue

Division of Gastroenterology, Tohoku University Graduate School of Medicine, Tokyo, Japan

### Deadline for manuscript submissions

closed (31 December 2021)



## Viruses

an Open Access Journal  
by MDPI

Impact Factor 3.8  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/si/71777](https://mdpi.com/si/71777)

*Viruses*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.8  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

---

### Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).